ATE511856T1 - Blockieren der leukozytenemigration und entzündung durch störung mit cd99/hec2 - Google Patents

Blockieren der leukozytenemigration und entzündung durch störung mit cd99/hec2

Info

Publication number
ATE511856T1
ATE511856T1 AT01920325T AT01920325T ATE511856T1 AT E511856 T1 ATE511856 T1 AT E511856T1 AT 01920325 T AT01920325 T AT 01920325T AT 01920325 T AT01920325 T AT 01920325T AT E511856 T1 ATE511856 T1 AT E511856T1
Authority
AT
Austria
Prior art keywords
tem
hec2
disruption
inflammation due
pecam
Prior art date
Application number
AT01920325T
Other languages
English (en)
Inventor
William Muller
Alan Schenkel
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Application granted granted Critical
Publication of ATE511856T1 publication Critical patent/ATE511856T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
AT01920325T 2000-03-13 2001-03-13 Blockieren der leukozytenemigration und entzündung durch störung mit cd99/hec2 ATE511856T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18880400P 2000-03-13 2000-03-13
PCT/US2001/007963 WO2001068131A1 (en) 2000-03-13 2001-03-13 Blocking leukocyte emigration and inflammation by interfering with cd99/hec2

Publications (1)

Publication Number Publication Date
ATE511856T1 true ATE511856T1 (de) 2011-06-15

Family

ID=22694585

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01920325T ATE511856T1 (de) 2000-03-13 2001-03-13 Blockieren der leukozytenemigration und entzündung durch störung mit cd99/hec2

Country Status (6)

Country Link
US (2) US7223395B2 (de)
EP (1) EP1276500B1 (de)
AT (1) ATE511856T1 (de)
CA (1) CA2402530C (de)
ES (1) ES2368419T3 (de)
WO (1) WO2001068131A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091730A1 (en) * 2002-04-24 2003-11-06 Surface Logix, Inc. Device and method for monitoring leukocyte migration
AU2004272093A1 (en) * 2003-09-11 2005-03-24 Entelos, Inc. Treatment of rheumatoid arthritis with CD99 antagonists
CN101099084A (zh) * 2004-12-14 2008-01-02 弗·哈夫曼-拉罗切有限公司 作为胰岛素耐受性的靶标/标记的cd99
WO2007005898A2 (en) * 2005-07-05 2007-01-11 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99l2
KR100793947B1 (ko) 2006-06-30 2008-01-16 강원대학교산학협력단 암세포의 성장 및 전이 억제 활성을 갖는 폴리펩타이드또는 그의 융합 단백질
WO2007037601A1 (en) * 2005-09-28 2007-04-05 Knu-Industry Cooperation Foundation Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof
WO2009052443A1 (en) 2007-10-19 2009-04-23 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
KR101074005B1 (ko) 2009-02-26 2011-10-17 재단법인춘천바이오산업진흥원 백혈구의 혈관외유출 억제 활성을 갖는 폴리펩타이드 또는 그의 융합 단백질
US8487131B2 (en) 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
AU2010236416A1 (en) 2009-04-15 2011-11-03 Sanford-Burnham Medical Research Institute Naphthalene-based inhibitors of anti-apoptotic proteins
EA201270347A1 (ru) * 2009-10-08 2012-11-30 Санфорд-Бернхам Медикал Ресерч Инститъют Производные апогоссиполона в качестве противоопухолевых агентов
KR101061017B1 (ko) * 2009-10-23 2011-08-31 (주) 수파드엘릭사 암세포의 성장 및/또는 전이 억제용 약학 조성물
US9901625B2 (en) 2011-10-15 2018-02-27 University Of Maryland, College Park Methods of regulating uptake and transcellular transport of leukocytes and therapeutics

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
CA1293460C (en) 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
WO1989012690A1 (en) 1988-06-13 1989-12-28 American Biogentic Sciences, Inc. Method for the production of monoclonal antibodies utilizing a germfree animal
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
FR2731230B1 (fr) * 1995-03-03 1997-05-30 Inst Nat Sante Rech Med Anticorps mono et polyclonaux diriges contre la region 63-75 de la proteine e2
JP3217703B2 (ja) * 1995-09-01 2001-10-15 株式会社東芝 磁性体デバイス及びそれを用いた磁気センサ
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5777195A (en) 1996-05-17 1998-07-07 The Rockefeller University Knockout mutant mouse for DARPP-32 and use thereof
JP2002515816A (ja) 1997-06-30 2002-05-28 アバンテイス・フアルマ・エス・アー ｉｎ ｖｉｖｏ組織に核酸ベクターを最適に電気導入する装置
BR9810372A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Processo de transferência de ácido nucléico para o interior de células de organismos eucarióticos pluricelulares in vivo, composição, ácido nucléico e campo elétrico, e, produto de combinação
DE69826124T3 (de) 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel

Also Published As

Publication number Publication date
EP1276500A4 (de) 2003-04-09
CA2402530C (en) 2014-01-14
US7223395B2 (en) 2007-05-29
WO2001068131A1 (en) 2001-09-20
US20070154450A1 (en) 2007-07-05
ES2368419T3 (es) 2011-11-17
CA2402530A1 (en) 2001-09-20
EP1276500A1 (de) 2003-01-22
US20030211099A1 (en) 2003-11-13
EP1276500B1 (de) 2011-06-08

Similar Documents

Publication Publication Date Title
ATE511856T1 (de) Blockieren der leukozytenemigration und entzündung durch störung mit cd99/hec2
ATE359271T1 (de) Phenylderivate
NO20002958L (no) Benzamidinderivater som koagulasjonsfaktor Xa-hemmere
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
DK1161235T3 (da) Kombinationer til behandling af sygdomme, der involverer angiogenese
DE60222238D1 (de) Zusammensetzung und verfahren zur perkutanen superoxygenierung
HUP0301577A2 (hu) Spiro-pirimidin-2,4,6-trion metalloproteináz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE50207442D1 (de) Behandlung der akne mit lipoxygenase inhibitoren
DE60135732D1 (de) Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
WO1999062510A3 (en) Compositions comprising anti-microtubule agents for treating or preventing inflammatory diseases
DE69108048D1 (de) Derivate von hydroxaminsäure und von n-hydroxyharnstoff sowie ihre verwendung.
DE69739656D1 (de) 1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe
ATE284860T1 (de) Neue verwendung von phenylheteroalkylamin- derivaten
DK1397105T3 (da) Præparat til inhibering af angiogenese
WO2001087838A8 (en) Cyclohexane derivatives and their use as therapeutic agents
TR199802060T2 (xx) Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
NO20025510D0 (no) Tienodibenzoazulenforbindelser som tumor nekrose faktor inhibitorer
IS2613B (is) Útskipt díketópíperasín sem oxýtósínblokkar
SE9902267D0 (sv) New compounds
ATE402166T1 (de) Substituierte-1-phthalazinamine als vr-1- antagonisten
ATE367390T1 (de) Phenylalanin enamidderivate
WO2007005898A3 (en) Blocking leukocyte emigration and inflammation by interfering with cd99l2
DK1450792T3 (da) Benzazolderivater til behandling af sclerodermia
DE69530429D1 (de) Catecholdiether-derivate verwendbar als pharmazeutische mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties